title: Helicobacter pylori eradication has no effect on metabolic and inflammatory parameters.
abstract: BACKGROUND
  An increased risk in coronary heart disease associated with Helicobacter pylori (H. pylon) appears to be partially mediated by modifications of the atherogenic lipoprotein and inflammatory parameters. We conducted a controlled trial aimed at evaluating the changes of metabolic and inflammatory parameters after H. pylon eradication.
  
  
  METHODS
  We included in the study 169 patients with H. pylori infection and conducted a retrospective longitudinal survey of 87 subjects (76 men, 11 women) who received treatment for H. pylon eradication and 82 control subjects (63 men, 19 women) who did not receive treatment. We compared pre- and posteradication (one year after) the metabolic and inflammatory parameters, such as blood sugar, lipid profiles, insulin resistance, white blood cell count and C-reactive protein.
  
  
  RESULTS
  No significant changes from the baseline in metabolic and inflammatory parameters within each group were observed. Changes in the serum levels of metabolic and inflammatory parameters were similar between the two groups.
  
  
  CONCLUSIONS
  Metabolic and inflammatory parameters, including blood sugar, lipid profiles, insulin resistance, white blood cell count and C-reactive protein, were not changed after H. pylori eradication treatment. H. pylori eradication has no effect on metabolic and inflammatory parameters.
authors.affiliation: Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Seung Ha
authors.initials: SH
authors.lastname: Park
authors.forename: Woo Kyu
authors.initials: WK
authors.lastname: Jeon
authors.forename: Sang Hoon
authors.initials: SH
authors.lastname: Kim
authors.forename: Hong Joo
authors.initials: HJ
authors.lastname: Kim
authors.forename: Dong Il
authors.initials: DI
authors.lastname: Park
authors.forename: Yong Kyun
authors.initials: YK
authors.lastname: Cho
authors.forename: In Kyung
authors.initials: IK
authors.lastname: Sung
authors.forename: Chong Il
authors.initials: CI
authors.lastname: Sohn
authors.forename: Byung Ik
authors.initials: BI
authors.lastname: Kim
authors.forename: Dong Keuk
authors.initials: DK
authors.lastname: Keum
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents; D016022:Case-Control Studies; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D005753:Gastric Mucosa / Q000473:pathology; D005756:Gastritis / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology*; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D018836:Inflammation Mediators / Q000032:analysis / Q000378:metabolism; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011336:Probability; D011379:Prognosis; D012016:Reference Values; D012189:Retrospective Studies; D018570:Risk Assessment
chemical_list: D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D018836:Inflammation Mediators